Thus, while targeting IL-33 could represent a novel therapeutic approach to stop the progression of gastritis to cancer in the early phases of tumorigenesis, at this stage, we cannot exclude that IL-33 may have a role in antitumoral activity in the advanced stage of gastric cancer. Here, IL33 is linked to gastritis.